After NICE okay, Scots denied access to Vifor’s Veltassa

The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even

Vifor forges iron drug partnership with Fresenius in China

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs.

Vifor joins forces with Evotec on kidney disease joint ventu...

AZ's potassium drug Lokelma finally approved in US

AstraZeneca badly needs new drugs on the market as several former blockbusters have been hit by generic competition – and finally its high potassium treatment Lokelma has been approved by U

EU approves AZ's potential blockbuster hyperkalaemia drug

After manufacturing issues, AstraZeneca hopes for FDA nod soon.